
Sign up to save your podcasts
Or


For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CPD/NCPD/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/WUM865. CME/MOC/CPD/NCPD/CPE/AAPA credit will be available until June 21, 2025.
Safeguarding Patients With HR+, HER2-, High-Risk, Early Breast Cancer: A Practical Roadmap for CDK4/6 Inhibition in the Adjuvant Setting
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an educational grant from Lilly.
Disclosure information is available at the beginning of the video presentation.
 By PVI, PeerView Institute for Medical Education
By PVI, PeerView Institute for Medical Education4.5
22 ratings
For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CPD/NCPD/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/WUM865. CME/MOC/CPD/NCPD/CPE/AAPA credit will be available until June 21, 2025.
Safeguarding Patients With HR+, HER2-, High-Risk, Early Breast Cancer: A Practical Roadmap for CDK4/6 Inhibition in the Adjuvant Setting
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an educational grant from Lilly.
Disclosure information is available at the beginning of the video presentation.

28 Listeners

10 Listeners

5 Listeners

10 Listeners

4 Listeners

2 Listeners

4 Listeners

2 Listeners

3 Listeners

5 Listeners

5 Listeners

2 Listeners

0 Listeners

9 Listeners

2 Listeners

11 Listeners

4 Listeners

3 Listeners

5 Listeners